Aprea Therapeutics

APREPhase 3

Doylestown, United Statesaprea.com

Aprea Therapeutics is a precision oncology company headquartered in Doylestown, Pennsylvania, focused on developing novel therapeutics that target the DNA Damage Response (DDR) pathways cancer cells rely on for survival. Its core strategy leverages synthetic lethality, aiming to selectively kill cancer cells with specific genetic mutations while sparing healthy tissue. The company's two lead clinical-stage assets, APR-1051 and ATRN-119, are in Phase 1 trials for biomarker-defined advanced solid tumors, with key data readouts anticipated in 2026. Aprea's approach is built on foundational research from its scientific team, positioning it as a player in the competitive but high-potential DDR inhibitor space.

Market Cap

$1.1B

Focus

Small Molecules

APRE · Stock Price

USD 92.80317.20 (-77.37%)

Historical price data

AI Company Overview

Technology Platform

A DNA Damage Response (DDR) targeted therapy platform leveraging synthetic lethality, focused on developing selective small molecule inhibitors (e.g., against ATR, WEE1) designed to kill cancer cells with specific genetic mutations while sparing healthy tissue.

Pipeline Snapshot

14 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
APR-246 + azacitidine + Azacitidine	MDS	Phase 3
APR-246	Acute Myeloid Leukemia or Myelodysplastic Syndromes	Phase 2
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	High-grade Serous Ovarian Cancer	Phase 2
APR-246 (eprenetapopt) + Pembrolizumab	Bladder Cancer	Phase 1/2
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d +...	Non Hodgkin Lymphoma	Phase 1/2

Funding History

Total raised: $110M

IPO$60MUndisclosedOct 3, 2019

Series B$30MUndisclosedJun 15, 2015

Series A$20MUndisclosedJun 15, 2012

Opportunities

Aprea's primary growth opportunity lies in successfully demonstrating clinical proof-of-concept for its selective DDR inhibitors in biomarker-defined cancers, which could lead to accelerated development paths and high-value partnerships.

Expansion into combination therapies with chemotherapy, PARP inhibitors, or immunotherapy represents a significant future avenue to address broader patient populations and overcome resistance mechanisms.

Risk Factors

The company faces high clinical development risk, with its entire value dependent on unproven Phase 1 assets.

Financial risk is acute as a micro-cap, pre-revenue company needing to fund expensive trials, risking shareholder dilution.

Intense competition in the DDR space from larger, better-funded players poses a significant commercial threat.

Competitive Landscape

Aprea competes in the crowded DDR inhibitor space against companies like AstraZeneca (WEE1/ATR), Bayer (ATR), and Repare/Roche (ATR). Its differentiation strategy is based on developing next-generation, more selective compounds (APR-1051 vs. adavosertib) and novel chemotypes (macrocyclic ATRN-119), coupled with a focused, biomarker-driven clinical development plan to demonstrate superior therapeutic windows.